News

Researchers have developed a non-invasive blood test that can detect whether a person has one of five common types of cancers (stomach, esophageal, colorectal, lung and liver cancer) four years before the condition can be diagnosed with current methods.

New modeling suggests that delays in patients presenting and being referred with suspected cancer by their doctor, and resulting bottlenecks in diagnostic testing, are likely to have had a significant adverse effect on patient survival.

Quadruple helix structures had previously been detected in cells. However, the technique used meant either killing the cells or using high concentrations of chemical probes to visualize G4 formation, so their actual presence within living cells in normal conditions had not been tracked, until now.

Preliminary data shows that immunotherapy doesn't necessarily worsen complications for patients with both COVID-19 and cancer.

Researchers have linked a new class of nanomaterials, called metal-organic frameworks, with the ligands of an existing photodynamic therapy drug to create a nanoporous material that is able to target and kill tumor cells without causing toxicity in healthy cells.

Cold Spring Harbor Laboratory (CSHL) Associate Professor Mikala Egeblad and her colleagues describe a newly understood way by which breast cancer cells sabotage a key player in the body’s immune system.

Researchers have developed a new technology that allows sensitive, quick and cost-effective identification of cancer biomarkers.

Scientists have identified an oncogene AVIL responsible for glioblastoma, the deadliest brain tumor. The discovery offers a promising new treatment target.

Researchers have used MALDI imaging mass spectrometry and immunohistochemistry to seek tumor-specific expression of proteins and lipids.

Scientists have revealed details of the discovery of a new cancer drug called fadraciclib, that could be used to treat a range of cancer types, including blood cancers and solid tumors.